Phaseline

Companies › Xilio Development

Xilio Development: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XTX301–Phase 1Advanced Solid TumorSep 2028
XTX501
CD27 agonist
CD27Phase 1Metastatic NSCLC - Non-Small Cell Lung CancerNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05684965XTX301Phase 1Advanced Solid TumorOncologySep 2028
NCT07688577XTX501Phase 1Metastatic NSCLC - Non-Small Cell Lung CancerOncologyNov 2029

Targets

CD27 (1)

Companies with the same targets

Alpine Immune Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.